Kardigan (NASDAQ:KARD) Price Target Cut to $36.00 by Analysts at Leerink Partners

Kardigan (NASDAQ:KARD) had its price target lowered by Leerink Partners from $37.00 to $36.00 in a research report released on Friday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

KARD has been the subject of a number of other reports. Cantor Fitzgerald initiated coverage on Kardigan in a report on Thursday, October 29th. They set an “overweight” rating and a $50.00 price target for the company. UBS Group initiated coverage on Kardigan in a research report on Monday, October 12th. They set a “buy” rating and a $25.00 price objective for the company. Weiss Ratings downgraded Kardigan from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday. HC Wainwright began coverage on Kardigan in a research report on Wednesday, November 4th. They set a “buy” rating and a $42.00 target price on the stock. Finally, Wall Street Zen lowered Kardigan from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.00.

Kardigan Trading Down 2.1%

Shares of Kardigan stock traded down $0.30 during trading on Friday, hitting $13.82. 410,885 shares of the stock were exchanged, compared to its average volume of 511,833. The company has a market cap of $1.29 billion and a PE ratio of -4.80. The business’s 50-day simple moving average is $15.14. Kardigan has a 12-month low of $12.23 and a 12-month high of $27.00.

Kardigan (NASDAQ:KARD) last issued its earnings results on Thursday, November 12th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.16. On average, equities analysts forecast that Kardigan will post -3.55 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of KARD. Jump Financial LLC purchased a new position in shares of Kardigan in the 3rd quarter valued at $304,000. State Street Corp acquired a new stake in Kardigan during the 3rd quarter worth $6,721,000. Russell Investments Group Ltd. acquired a new stake in Kardigan during the 3rd quarter worth $31,000. China Universal Asset Management Co. Ltd. purchased a new stake in Kardigan in the third quarter valued at $47,000. Finally, Squarepoint Ops LLC purchased a new stake in Kardigan in the second quarter valued at $247,000.

Top Kardigan Stories

These are some of the KARD stories that stood out recently:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $42 price target. It also raised its FY2026 estimate to a loss of $3.70 per share from $4.01, and improved estimates for FY2028, FY2029 and FY2030. Kardigan analyst estimates
• Negative Sentiment: The firm cut estimates for multiple 2027 quarters and lowered its FY2027 forecast to a loss of $3.47 per share from $3.29, signaling expectations for higher losses over that period. A separate Leerink Partners update trimmed its price target to $36 from $37, though it retained an Outperform rating.

About Kardigan

Kardigan is a biopharmaceutical company focused on developing medicines for cardiovascular diseases. Its work centers on advancing therapeutic candidates intended to address heart and vascular conditions. The company’s activities include research and development of a pipeline of cardiovascular drug candidates. Kardigan was launched as a biotechnology company in 2024; detailed information about its commercial products and geographic operations is limited.